Applying Evidence-Based Treatment Strategies in NSCLC with KRAS Mutations

Overview

Intended Audience: Teams caring for patients with NSCLC (physicians, PAs, NPs, pharmacists, nurses specializing in oncology)

KRAS G12C-positive non-small cell lung cancer (NSCLC) is a sizable patient group with new and emerging targeted therapy options. Management of these patients will evolve as clinical efficacy and safety data continue to emerge, and as guidelines are updated. Take part in this timely, interactive update from NSCLC experts on how the therapies work and the clinical data guiding optimal use, as well as how to integrate the care of these patients into current evidence-based management of patients with NSCLC.

Learning Objectives

Evaluate recent safety and efficacy data on KRAS-targeted therapies in NSCLC
Develop evidence-based, biomarker-directed treatment plans for patients with NSCLC

Agenda

Practice Insights: Lessons From a New Survey in NSCLC
Mechanisms of Action of Novel KRAS inhibitors
Clinical Safety and Efficacy Data Guiding the Use of Novel KRAS Inhibitors
Case Discussion: Integrating Novel Evidence Into Biomarker-Directed Treatment Decisions

Faculty

Gilberto de Lima Lopes, Jr, MD, MBA, FAMS

Course Director and Speaker

Professor of Clinical Medicine
Medical Director, International Programs
Associate Director, Global Oncology
Interim Chief, Division of Medical Oncology
University of Miami Sylvester Comprehensive Cancer Center
Miami, FL

Soo-Ryum Yang, MD

Speaker

Assistant Attending Pathologist
Memorial Sloan Kettering Cancer Center
New York, NY

Douglas S Burgoyne, PharmD, FAMCP

Moderator

Adjunct Associate Professor
Department of Pharmacotherapy
University of Utah College of Pharmacy
Salt Lake City, UT

Mark A Rubin, MD

Planner

Medical Director
Humana
Fort Lauderdale, FL

Ryan M Burke, PharmD

Planner

Director, Professional Affairs
Pharmacy Technician Certification Board
Washington, DC

Judith R Sands, RN, MSL, BSN, CCM, CPHQ, CPHRM, ARM

Peer Reviewer

Clinical Consultant
Raleigh, NC

CE Details & Instructions

Joint Accreditation Statement

In support of improving patient care, PRIME® is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Interprofessional Teams

This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credits for learning and change.

Physician Credit Designation Statement

PRIME® designates this Live activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

MOC Points

ACCME MOC Logo Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Physician Assistant Accreditation Statement

PRIME® has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation.

Nurse Practitioner Accreditation Statement

Nurse Practitioner Logo PRIME Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 060815. This activity is approved for 0.5 contact hour (which includes 0 hour of pharmacology).

Pharmacist Accreditation Statement

This Application-based activity has been approved for 0.5 contact hour (0.05 CEUs) by PRIME® for pharmacists. The Universal Activity Number for this activity is JA0007144-0000-21-149-L01-P . Pharmacy CE credits can be submitted to the NABP upon successful completion of the activity by providing your NABP ID & DOB, which must be submitted within 60 days of completion. Pharmacists with questions can contact NABP customer service ([email protected]).

Nurse Accreditation Statement

PRIME® designates this activity for 0.5 contact hour.

Obtaining CE Credit

Register using the online form
Complete the pre-registration survey
Attend the live program in its entirety
Complete an online evaluation and post-test
Download and/or print a certificate of completion and/or submit CE credits electronically

Instructions to access CME/CE credit options will be provided at the end of the program.

Method of Participation

This live CME/CE activity requires attendance of the participant during the entire program and completion of learner assessment tools. The learner will then receive instructions on how to download and/or print a certificate of completion and/or submit CE credits electronically.

Device Requirements

Hardware: an Internet-enabled computer, smartphone, tablet, or mobile device with audio capabilities and Internet connectivity
Software: the installation of software such as GoToWebinar may be required

Faculty Disclosures

*PRIME® has identified, reviewed, and mitigated all conflicts of interest that speakers, authors, course directors, planners, peer reviewers, or relevant staff disclose prior to the delivery of any educational activity.

The following individuals have identified relevant financial relationships with commercial interests to disclose:

Gilberto de Lima Lopes, Jr, MD, MBA, FAMS (Course Director, Speaker)

Consultant – AstraZeneca, Pfizer
Grants / Research Support – AbbVie, Adaptimmune, AstraZeneca, Bavarian Nordic, Blueprint Medicines, Bristol-Myers Squibb, EMD Serono, ER Squibb Sons LLC, G1 Therapeutics, GlaxoSmithKline, Janssen, Lilly, Lucence, Merck Sharp & Dohme, Novartis, Pfizer, Rgenix, Roche, Tesaro, Xilis
Other Financial or Material Support (royalties, patents, etc.) – Boehringer Ingelheim, Celgene, ER Squibb Sons LLC, Janssen, Pfizer, Seagen (Seattle Genetics)
Soo-Ryum Yang, MD (Speaker)

Consultant – Invitae

The following individuals have no relevant financial relationships with commercial interests to disclose:

Douglas S Burgoyne, PharmD, FAMCP (Moderator)
Judith R Sands, RN, MSL, BSN, CCM, CPHQ, CPHRM, ARM (Reviewer)
Mark A Rubin, MD (Planner)
Ryan M Burke, PharmD (Planner)

All PRIME® staff participating in planning and content development have no relevant financial relationships with commercial interests to disclose.

Funding Disclosure

This activity is provided by PRIME Education. There is no fee to participate.This activity is supported by an educational grant from the Bristol Myers Squibb and Pfizer Alliance.

Accessibility Statement

At PRIME, we are committed to ensuring that individuals with disabilities can access all of the content offered by PRIME through our website and other properties. If you are having trouble accessing primeinc.org, please email [email protected] for assistance. Please put "ADA Inquiry" in the subject line of your email.

Summary


Cost:	FREE


Credit:	No Credit Offered

Create Account